156 related articles for article (PubMed ID: 29081197)
1. [Clinical features and prognosis of 17 patients with primary cold agglutinin disease].
Wu YY; Cao XX; Cai H; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):789-793. PubMed ID: 29081197
[No Abstract] [Full Text] [Related]
2. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
[No Abstract] [Full Text] [Related]
4. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
[TBL] [Abstract][Full Text] [Related]
5. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins).
Crisp D; Pruzanski W
Am J Med; 1982 Jun; 72(6):915-22. PubMed ID: 6807086
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Features and Outcomes of the Patients with B-Cell Chronic Lymphoproliferative Disease in the New Drug Era].
Xu CB; Hu M; Shen JZ; Xu HQ; Zheng RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):722-729. PubMed ID: 37356932
[TBL] [Abstract][Full Text] [Related]
7. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia.
Berentsen S
Clin Lymphoma Myeloma; 2009 Mar; 9(1):110-2. PubMed ID: 19362990
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.
Tanaka H; Hashimoto S; Sugita Y; Sakai S; Takeda Y; Abe D; Takagi T; Nakaseko C
Int J Hematol; 2012 Oct; 96(4):501-5. PubMed ID: 22878940
[TBL] [Abstract][Full Text] [Related]
9. [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
[TBL] [Abstract][Full Text] [Related]
10. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.
Berentsen S; Ulvestad E; Langholm R; Beiske K; Hjorth-Hansen H; Ghanima W; Sørbø JH; Tjønnfjord GE
Haematologica; 2006 Apr; 91(4):460-6. PubMed ID: 16585012
[TBL] [Abstract][Full Text] [Related]
11. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
[TBL] [Abstract][Full Text] [Related]
12. The Histopathology of Cold Agglutinin Disease-Associated B-Cell Lymphoproliferative Disease.
Guenther A; Tierens A; Malecka A; Delabie J
Am J Clin Pathol; 2023 Sep; 160(3):229-237. PubMed ID: 37253147
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients.
Jia MN; Qiu Y; Wu YY; Cai H; Zhou DB; Cao XX; Li J
Sci Rep; 2020 Jul; 10(1):12694. PubMed ID: 32728060
[TBL] [Abstract][Full Text] [Related]
14. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
[TBL] [Abstract][Full Text] [Related]
15. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
16. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
17. [Successful treatment with rituximab in a patient with splenic marginal zone B-cell lymphoma accompanied by cold agglutinin disease].
Yasuyama M; Kawauchi K; Otsuka K; Tamura H; Fujibayashi M
Nihon Ronen Igakkai Zasshi; 2014; 51(6):569-75. PubMed ID: 25749330
[TBL] [Abstract][Full Text] [Related]
18. Frostbite and Cold Agglutinin Disease: Coexistence of Two Entities Leading to Poor Clinical Outcomes.
Lorenzo-Villalba N; Andres E; Guerrero-Niño J; Nasco E; Cattelan J; Jannot X; Ledoux MP
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34201186
[TBL] [Abstract][Full Text] [Related]
19. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
[TBL] [Abstract][Full Text] [Related]
20. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
